{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:07:46Z","timestamp":1793642866123,"version":"4.5.1"},"reference-count":91,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T00:00:00Z","timestamp":1508371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Advancements in the immunopathogenesis of psoriasis have identified interleukin (IL)\u201023 and IL\u201017 as fundamental contributors in the immune pathways of the disease. Leveraging these promising therapeutic targets has led to the emergence of a number of anti\u2010IL\u201023 and \u201017 biologic agents with the potential to treat multiple conditions with common underlying pathology. The unprecedented clinical efficacy of these agents in the treatment of psoriasis has paved way for their evaluation in diseases such as psoriatic arthritis, Crohn's disease, rheumatoid arthritis, in addition to other immune\u2010mediated conditions. Here we review the IL\u201023\/IL\u201017 immune pathways and discuss the key clinical and safety data of the anti\u2010IL\u201023 and anti\u2010IL\u201017 biologic agents in psoriasis and other immune\u2010mediated diseases.<\/jats:p>","DOI":"10.1002\/cpt.893","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T15:58:30Z","timestamp":1506614310000},"page":"88-101","source":"Crossref","is-referenced-by-count":65,"title":["Anti\u2010IL\u201023 and Anti\u2010IL\u201017 Biologic Agents for the Treatment of Immune\u2010Mediated Inflammatory Conditions"],"prefix":"10.1111","volume":"103","author":[{"given":"Jillian","family":"Frieder","sequence":"first","affiliation":[{"name":"Baylor Scott and White, Division of Dermatology Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Kivelevitch","sequence":"additional","affiliation":[{"name":"Baylor Scott and White, Division of Dermatology Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Haugh","sequence":"additional","affiliation":[{"name":"Baylor Scott and White, Division of Dermatology Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Watson","sequence":"additional","affiliation":[{"name":"Texas A&amp;M College of Medicine Bryan Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Menter","sequence":"additional","affiliation":[{"name":"Baylor Scott and White, Division of Dermatology Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,19]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04754"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05505"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2799"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700499200"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0083-6729(06)74010-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0414-y"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200385"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.1.65"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12487"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1737-y"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512468497"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201405-0859PP"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin\u201012\/23 monoclonal antibody, in patients with psoriasis: 76\u2010week results from a randomised, double\u2010blind, placebo\u2010controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi C.L.","year":"2006","journal-title":"Lancet"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13469"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"},{"key":"e_1_2_8_23_1","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque\u2010type psoriasis: results from a phase 3 Clinical trial (LOTUS)","volume":"12","author":"Zhu X.","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.002"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70173-X"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13112"},{"key":"e_1_2_8_31_1","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp K.","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1211"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.163"},{"key":"e_1_2_8_34_1","volume-title":"Siliq [package insert]","year":"2017"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0121-x"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13785"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201212-2318OC"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500909"},{"key":"e_1_2_8_43_1","unstructured":"Highlights of Prescribing Information[Revised February 2017] [Accessed August 29 2017]. Available from: <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf>"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.057"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1228872"},{"key":"e_1_2_8_46_1","unstructured":"U.S. Food and Drug Administration.Approved Risk Evaluation and Mitigation Strategies (REMS) [Internet]. Accessed 29 August 2017. Available from: <https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm?event=IndvRemsDetails.page&REMS=362>2017."},{"key":"e_1_2_8_47_1","volume-title":"Ixekizumab [prescribing information]","year":"2017"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38617"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140831"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"e_1_2_8_54_1","volume-title":"Cosentyx [prescribing information]","year":"2016"},{"key":"e_1_2_8_55_1","unstructured":"Novartis Pharmaceuticals Corporation [Advisory Committee Briefing Material for Cosentyx]. Switzerland. <https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/UCM419023.pdf>. Accessed 28 June2017."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12110"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12112"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"key":"e_1_2_8_59_1","first-page":"1226","article-title":"Secukinumab self\u2010administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial","volume":"15","author":"Gottlieb A.B.","year":"2016","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_60_1","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.15656","article-title":"Secukinumab re\u2010initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis","author":"Blauvelt A.","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13814"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209055"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23111"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40070"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.040"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2012.690902"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep28586"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15015"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.175"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2003.09.013"},{"key":"e_1_2_8_79_1","first-page":"8","article-title":"A review of guselkumab, an IL\u201023 inhibitor, for moderate\u2010to\u2010severe plaque psoriasis","volume":"22","author":"Nawas Z.","year":"2017","journal-title":"Skin Ther. Lett."},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_8_82_1","unstructured":"New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira in Treatment of Moderate to Severe Plaque Psoriasis [internet].2017[cited 20 June 2017]. Available from: <https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/new\u2010results\u2010from\u2010second\u2010phase\u20103\u2010study\u2010show\u2010significant\u2010efficacy\u2010of\u2010guselkumab\u2010and\u2010superiority\u2010versus\u2010humira\u2010in\u2010treatment\u2010of\u2010moderate\u2010to\u2010severe\u2010plaque\u2010psoriasis>"},{"issue":"10","key":"e_1_2_8_83_1","article-title":"Efficacy and safety results of guselkumab, an anti\u2010IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double\u2010blind, placebo\u2010controlled study [abstract]","volume":"68","author":"Deodhar G.A.","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209831"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_2_8_89_1","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","author":"Reich K.","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_8_90_1","unstructured":"Sands B.E.Abstract 830[abstract presented at: Digestive Disease Week; Washington D.C.] (2015)."},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.07.010"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.893","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:33:00Z","timestamp":1699363980000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,19]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/cpt.893"],"URL":"https:\/\/doi.org\/10.1002\/cpt.893","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,19]]}}}